A
Allan T. van Oosterom
Researcher at The Catholic University of America
Publications - 14
Citations - 22501
Allan T. van Oosterom is an academic researcher from The Catholic University of America. The author has contributed to research in topics: Rash & Imatinib mesylate. The author has an hindex of 12, co-authored 14 publications receiving 21784 citations. Previous affiliations of Allan T. van Oosterom include Oregon Health & Science University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
New guidelines to evaluate the response to treatment in solid tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: In this article, the authors proposed a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment.
Journal ArticleDOI
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri,Allan T. van Oosterom,Christopher R. Garrett,Martin E. Blackstein,Manisha H. Shah,Jaap Verweij,Grant A. McArthur,Ian Judson,Michael Heinrich,Jeffrey A. Morgan,Jayesh Desai,Christopher D.M. Fletcher,Suzanne George,Carlo L. Bello,Xin Huang,Charles M. Baum,Paolo G. Casali +16 more
TL;DR: A randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumour, noting significant clinical benefit, including disease control and superior survival.
Journal ArticleDOI
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Allan T. van Oosterom,Ian Judson,Jaap Verweij,Sigrid Stroobants,Eugenio Donato di Paola,Sasa Dimitrijevic,Marc Martens,Andrew Webb,Raf Sciot,Martine Van Glabbeke,Sandra Silberman,Ole S. Nielsen +11 more
TL;DR: Impatinib at a dose of 400 mg twice daily is well tolerated during the first 8 weeks, side-effects diminish with continuing treatment, and it has significant activity in patients with advanced GISTs.
Journal ArticleDOI
Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)
Michael Heinrich,Grant A. McArthur,George D. Demetri,Heikki Joensuu,Petri Bono,Richard Herrmann,Hal Hirte,Sara Cresta,D. Bradley Koslin,Christopher L. Corless,Stephan Dirnhofer,Allan T. van Oosterom,Zariana Nikolova,Sasa Dimitrijevic,Jonathan A. Fletcher +14 more
TL;DR: Imatinib response in AF patients may be mediated by inhibition of PDGFRB kinase activity, and imatinib is an active agent in the treatment of advanced AF.